RTS,S/AS01

RTS,S/AS01, marketed as Mosquirix, is the world's first approved vaccine for the prevention of malaria caused by the Plasmodium falciparum parasite. Developed through a decades-long partnership between GlaxoSmithKline and the PATH Malaria Vaccine Initiative, with funding from the Bill & Melinda Gates Foundation, it represents a landmark achievement in tropical medicine. The vaccine is designed for children in regions with moderate to high malaria transmission and received a historic recommendation from the World Health Organization in 2021.

Development and Composition

The development of RTS,S/AS01 began in the 1980s at the Walter Reed Army Institute of Research, with major pharmaceutical collaboration later undertaken by GlaxoSmithKline. Its composition is a recombinant protein-based subunit vaccine, fusing a portion of the circumsporozoite protein from *Plasmodium falciparum* with the hepatitis B surface antigen, creating a virus-like particle. The AS01 adjuvant system, containing MPL and QS-21 sourced from the Chilean soapbark tree, is a critical component that enhances the immune response. This long-term research effort involved numerous clinical sites across Africa, supported by entities like the European Union and the United States Agency for International Development.

Clinical Efficacy and Trials

The vaccine's efficacy was established through a massive clinical development program, most notably the Phase III trial conducted across eleven sites in seven sub-Saharan African countries, including Ghana, Kenya, and Malawi. Published in The New England Journal of Medicine, data showed that over four years, four doses provided approximately 36% protection against clinical malaria in children aged 5-17 months. A subsequent pilot implementation program, coordinated by the World Health Organization, evaluated real-world feasibility in Rwanda, Ghana, and Malawi, assessing integration into routine immunization schedules alongside other interventions like insecticide-treated bed nets.

Mechanism of Action

RTS,S/AS01 targets the pre-erythrocytic stage of the Plasmodium falciparum life cycle, aiming to prevent infection of the liver. It induces high levels of antibodies against the circumsporozoite protein, which coats the sporozoite injected by the Anopheles mosquito. These antibodies, along with a cell-mediated response primed by the AS01 adjuvant, work to neutralize the parasites before they can establish hepatic infection and progress to cause the symptomatic blood-stage disease. This mechanism complements other control strategies that target the mosquito vector or the later blood stage parasites.

Regulatory Approval and Deployment

Following the positive results from the pilot program, the World Health Organization issued a landmark recommendation for widespread use in October 2021. This paved the way for eligibility for funding from Gavi, the Vaccine Alliance, which approved a support program to facilitate introduction. Regulatory approval had previously been granted by the European Medicines Agency in 2015 under Article 58. Initial rollout is focused on regions with moderate-to-high malaria transmission in Africa, with national immunization programs in countries like Cameroon and Burkina Faso beginning distribution in early 2024.

Impact and Public Health Significance

The introduction of RTS,S/AS01 marks a transformative moment in the global fight against malaria, a disease that causes hundreds of thousands of childhood deaths annually, primarily in Africa. While not a silver bullet, it is a powerful new tool to be used alongside core interventions like insecticide-treated nets and artemisinin-based combination therapies. Its development demonstrates the potential of public-private partnerships involving GlaxoSmithKline, PATH, and the World Health Organization. The vaccine's deployment is expected to significantly reduce severe disease and child mortality, contributing to the goals outlined in the World Health Organization Global Technical Strategy for Malaria.

Category:Vaccines Category:Malaria